Cell Source, Inc. (CLCS) Stock Price & Analysis

Cell Source, Inc. (CLCS) rose 0.78% to USD 0.65 as of July 25, 2026 at 14:24 UTC, according to Nexqual real-time market data.

CLCS last closed at USD 0.65; the session ranged USD 0.65–0.65 on volume of 400 shares. Market capitalization is $44.16M, with a 52-week range of USD 0.3–2.25 (PNK). Source: Nexqual, July 25, 2026 at 14:24 UTC.

Key Statistics (as of July 25, 2026 at 14:24 UTC)

Technical Analysis (CLCS)

Nexqual's technical model rates CLCS "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 14:24 UTC.

Analyst Ratings (CLCS)

Wall Street analysts rate CLCS "None", per Nexqual as of July 25, 2026 at 14:24 UTC.

Earnings (CLCS)

Source: Nexqual, July 25, 2026 at 14:24 UTC.

Financials & Fundamentals (CLCS)

Source: Nexqual, July 25, 2026 at 14:24 UTC.

Financial Health Score (CLCS)

Nexqual rates Cell Source, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 14:24 UTC.

Ownership (CLCS)

Source: Nexqual, July 25, 2026 at 14:24 UTC.

Leadership (CLCS)

Cell Source, Inc. is led by Itamar Shimrat (age 66), CEO, President & CFO, per Nexqual as of July 25, 2026 at 14:24 UTC.

From Cell Source, Inc.'s Latest SEC 10-K Filing (filed 2026-04-07)

Key Strengths & Strategy (as disclosed to the SEC)

• High profile CAR-T acquisitions have included KITE Pharmaceuticals, a CAR-T cell therapy company, which was acquired outright by Gilead Sciences in 2017 for $11.9 billion in cash, prior to having attained FDA approval and prior to commencing any product sales, and Juno Therapeutics, which was acquired by Celgene Corporation in 2018 for approximately $9 billion, also without having FDA approval for its CAR-T cell therapy technology.
• Professor Richard Champlin (who Chairs their Department of Stem Cell Transplantation and Cellular Therapy and is a longtime associate and collaborator of Professor Reisner) serves as Principal Investigator for this trial.   Although Yeda has applied for and been granted various patents related to our technology, a granted patent only provides Yeda, and the Company by virtue of its exclusive license, the right to use the underlying invention.
• Our technology has immediate relevance for, at a minimum, the roughly 40,000 worldwide stem cell transplants that are allogeneic (using cells taken from another individual, not the patient).
• The key terms of the agreement pursuant to which we license all of Yeda's patents related to our technology is set forth in the section entitled "Intellectual Property" herein.

Partnerships

• The agreement was subsequently amended by an initial three month extension through February 28, 2025, and then again amended through March 31, 2026.   In February 2019, we executed a second agreement with MD Anderson for the production of Veto Cells and the conducting of a Phase ½ FDA trial for the Anti-Rejection, Anti-Viral Veto Cell.
• What follows is a description of the significance of these two new patent applications:           Cell Source previously completed a collaboration, through its licensing agreement with Yeda, with Professor Zelig Eshhar, the inventor of CAR-T cells.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 14:24 UTC. This page is informational and not investment advice.